Generative AI is entering clinical workflows just as healthcare institutions grapple with black-box outputs, unclear regulation, and the need for provable accuracy.
In this episode, Rhett Alden, CTO at Elsevier, joins Emerj's Yolandi de Weerdt to articulate how claim-level validation and transparent sourcing are becoming prerequisites for clinical trust in AI. The conversation covers emerging AI governance boards modeled on clinical trial review structures, the limits of current US regulation, and why final clinical responsibility remains with the physician.
Learn the strategies Emerj uses to help leading AI brands and startups connect with their ideal enterprise AI buyers:
emerj.com/AD1
